Trial Profile
Retrospective study investigating the efficacy of use of Azacitidine and donor lymphocyte infusions (DLIs) in patients with acute myeloid leukemia, myelodysplastic syndrome or myeloproliferative syndrome after allogenic hematopoietic stem cell transplantation (allo-HSCT)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2016
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; T cell replacement therapy (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
- Focus Therapeutic Use
- 05 Feb 2016 New trial record